Share: Facebook Twitter GooglePLus LinkedIn
Activity Provided By:

The Rx Consultant

New Drugs 2018

Access Activity

Overview / Abstract:

In 2018, the US Food and Drug Administration (FDA) approved 59 new drugs – the highest number in more than 10 years – including 19 first-in-class agents.

Of the 59 new approvals, 73% received priority review. This issue of The Rx Consultant focuses on the new drugs that may be important additions (including a number of “firsts”) in their therapeutic areas: influenza infection, HIV-1 infection, pneumonia and skin infections, nonmetastatic, castration-resistant prostate cancer, endometriosis, migraine prophylaxis, moderate to severe acne, and chronic, idiopathic constipation.

Dosing and drug interactions are detailed in Table 1. Brief descriptions of selected additional new drugs are shown in Table 2, and new HIV drugs and HIV drug combinations are decribed in Table 3. Table 4 lists selected new formulations or indications for previously approved drugs.

Expiration

Mar 22, 2022

Discipline(s)

Nursing CNE, Pharmacy CPE

Format

Monograph

Cost

$10.00

Credits / Hours

2.0

Accreditation

ACPE

Presenters / Authors / Faculty

James Chan, PharmD, PhD is an Associate Clinical Professor, School of Pharmacy, University of California, San Francisco, CA.

Pamela Mausner, MD is a Medical Writer / Editor for The Rx Consultant and Continuing Education Network, Inc.

Activity Specialities / Related Topics

Pharmacology

Keywords / Search Terms

Continuing Education Network Inc. Apalutamide, Baloxavir marboxil, Elagolix, Erenumabaooe, Fremanezumabvfrm, Galcanezumabgnlm, Lofexidine, Omadacycline, Prucalopride, Revefenacin, Sarecycline, Annovera

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map